Target PharmaSolutions Inc. is conducting longitudinal, observational studies of patients in non-alcoholic steatohepatitis (NASH) and three other diseases with an ultimate goal of providing clients with real-world data solutions that may help drug makers design clinical studies and commercialization plans, and streamline their compliance with FDA post-marketing requirements.
The privately held firm launched in 2015 to build upon an academic effort called HCV-TARGET, which enrolled more than 10,000 at 58 sites in North America and Europe and compiled...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?